VivoSim Labs (NASDAQ:VIVS – Get Free Report) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it contrast to its competitors? We will compare VivoSim Labs to related businesses based on the strength of its dividends, risk, analyst recommendations, valuation, earnings, profitability and institutional ownership.
Risk & Volatility
VivoSim Labs has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, VivoSim Labs’ competitors have a beta of 0.93, meaning that their average stock price is 7% less volatile than the S&P 500.
Valuation & Earnings
This table compares VivoSim Labs and its competitors gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| VivoSim Labs | $130,000.00 | -$13.84 million | -0.04 |
| VivoSim Labs Competitors | $2.33 billion | $55.11 billion | -7.49 |
VivoSim Labs’ competitors have higher revenue and earnings than VivoSim Labs. VivoSim Labs is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Analyst Recommendations
This is a summary of recent recommendations for VivoSim Labs and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VivoSim Labs | 1 | 0 | 0 | 0 | 1.00 |
| VivoSim Labs Competitors | 957 | 3194 | 5533 | 179 | 2.50 |
As a group, “Life Sciences Tools & Services” companies have a potential upside of 1.41%. Given VivoSim Labs’ competitors stronger consensus rating and higher possible upside, analysts plainly believe VivoSim Labs has less favorable growth aspects than its competitors.
Insider and Institutional Ownership
8.2% of VivoSim Labs shares are owned by institutional investors. Comparatively, 54.0% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 1.0% of VivoSim Labs shares are owned by insiders. Comparatively, 14.8% of shares of all “Life Sciences Tools & Services” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares VivoSim Labs and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| VivoSim Labs | -7,605.93% | -498.57% | -146.07% |
| VivoSim Labs Competitors | -487.63% | 79.17% | -12.95% |
Summary
VivoSim Labs competitors beat VivoSim Labs on 11 of the 13 factors compared.
VivoSim Labs Company Profile
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds.
Receive News & Ratings for VivoSim Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VivoSim Labs and related companies with MarketBeat.com's FREE daily email newsletter.
